Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
First, this is an OTCQB penny stock. There are many here, including speculators and market makers, who have short-term motives and are flipping or shorting the stock. It can be frustrating for longs who want to see a return on investment in a reasonable time frame. But as the CEO has stated numerous times in response to investor questions about share price, he can only focus on execution of the business plan. There is an expectation of greater appreciation in share price when good news hits once the stock trades on NASDAQ.
Second, reporting record testing sales isn't the same as seeing those number in the quarterly earnings report. For many folks, that is what they focus on. Gerald reported record sales for testing supplies last year, and then $7M of those revenues failed to be collected due to non-payment by the customer. That is still in everyone's mind, so the focus on SEC filings is understandable and the news alone doesn't move share price.
I picked up more Todos shares today, and expect to pick up more this week and next week. I previously stated I was done buying shares, but with the downward turn in share price it's hard to ignore when I firmly believe the phase 2 data will be very strong. I expect a partnership or buyout offer, perhaps competing offers, to be announced after the data is made public.
Good luck. Exciting weeks and months ahead. My outlook hasn't changed.
Sukyamadda, I think you're misunderstanding what Gerald stated. The Israeli law he spoke of was concerning capital restructuring, in which the ratio of outstanding to authorized shares must remain the same before and after the restructuring.
Example: If there are 5 billion shares authorized and 1 billion shares issued before a 1:10 RS, then both values have to adjust per the same 1:10 ratio. AS would be reduced to 500 million and OS would be reduced to 100 million in this scenario.
To my understanding, Israeli law doesn't restrict the current ratio of AS to OS, but it does require equal treatment in a capital restructuring. From your post, it appears you were trying to say the 1:5 ratio is required for the current share structure. If that is what you're trying to state, how would that make sense? The company couldn't exceed 1 billion shares issued without first voting to increase authorized shares to some value in excess of 5 billion shares.
We know how to read the filings and don't need a refresher course from chart traders or share flippers Chartists don't bother reading financials anyway. While we are all concerned about the outstanding share count, we follow it closely with weekly updates. Contrary to your claim, there are no shares allotted for unrestricted dumping. That's just clearly uninformed or possibly scare tactics for a motive not beneficial to shareholders.
Here's a summary of the share structure... much of 2021 was spent transferring convertible debt to quality venture cap firms like Yozma Group. These debt holders are in this for the long game, and as such have agreed twice concurrently to lock up their shares until the uplist. They're not converting the debt and dumping shares in the market as your posts would have us believe. It is not unexpected for many stocks to decline in the last 2 weeks of the year as investors sell to lock in tax losses. It's a clear buying opportunity for those who believe in the story unfolding here.
In addition, Gerald stated in a recent presentation that ALL convertible debt will be exchanged for preferred shares as part of the uplist to NASDAQ.
The only epic fail here will be for the short-term traders who might be sold out of their position when news of a major partnership or buyout hits the wires. Those of us who know the risk but know what we own aren't trading our shares.
I suggest one of the other boards where fear, uncertainty and misinformation might be more effective. This board is full of informed shareholders and those tactics are unlikely to work here. Everyone feel free to use the IGNORE feature as needed. GLTA Exciting times ahead.
Share Structure Update - 12/23/21
Zero shares added since last update on 12/17/21
https://www.otcmarkets.com/stock/TOMDF/security
It depends on your perspective. Gerald once reported monthly sales in tweets and press releases. It became an expectation for shareholders to get monthly updates, and when those updates didn't come investors got nervous and assumed the worst. Gerald announced he would stop providing monthly updates and instead report sales via quarterly reporting.
If one is interpreting Tollovid sales as those reported in filings, then no official sales have been reported since Q2 2021. If one is interpreting sales as comments Gerald has made in recent interviews, talking about peak days and averages over the last few weeks with the Omicron concerns, then sales figures have been provided.
Everyone has different perspectives and all are welcomed here. Please ask for clarification before posting what could be considered an attack against the poster. That might not have been the intent, but that's how some might interpret it.
Exciting times ahead for shareholders, but I suspect a bumpy road ahead as well for share price. Traders and MMs will play their trading games and create volatility, but I am holding for the longer game.
As the market closes today, I hope everyone will put their investment concerns aside for a few days and focus on being with family and friends, and the many blessings in our lives. In the end that's all that matters. And if we can provide our family and friends with a little Tollovid love, all the better. Very happy to be a part of this Todos story that's unfolding.
Wishing everyone a safe and enjoyable holiday. Merry Christmas to all.
Exactly.
What exactly is an "Operation Lock"?
Great read. Thanks for sharing.
If the market has figured out what a buy this is, then demand should be driving share price higher, right? Why would anyone be selling at this level?
I enjoyed the webinar and the presentations. Lots of good info and insight. I posed the question that Gerald answered regarding TolloTest and am looking forward to seeing this brought to market... a 10-minute test as accurate as PCR that can provide very early detection of infection. This test would virtually kill the market for other rapid tests and probably be another cash cow for the company. A fast, accurate, early detection test is desperately needed to limit spread of this rapidly mutating virus. 3CL protease early detection sounds like the way to do it.
Dr. Arad was surprising. You could see her excitement as she talked about her work and the results observed last year with both Tollovir and Tollovid. Happy that she's being recognized and rewarded for her work. Expecting to see news of the completion of the 3CL Sciences subsidiary any day now. I suspect the recent increase in authorized shares is related to this transaction.
Agree on the stinking part.
Anyone think this might go sub-penny by years end? Glad I got out when I did at 0.054. If it hits a penny I might pick up some shares again as a speculative investment.
GLTA
In the spirit of dragging up ancient history, I suppose it's time to start regurgitating posts made by certain shareholders who were pumping the hell out of AMBS as much as the CEO was on the blogs, leading others astray every bit as much as the CEO.
Would probably make certain shareholders look extremely gullible and naive, and easily duped. There's a wealth of posts to choose from, all relevant to complete the picture here of who was misleading who back then. Fools following the fool. Shall I continue?
Go back to the MONI board and try your luck there. Doesn't look good given the 6-month downward spiral. Perhaps one enjoys in losers over a 12-year period. Glad I got out of that turd before it really tanked. Might even go lower than AMBS share price by years end. LOL
This is the AMBS board. My investment here has been in the money ever since I made it. My TOMDF investment also doing very well. Company firing on all cylinders, and AMBS will be reborn here as well. CEO learned from mistakes made earlier with AMBS. Too bad you'll never give him credit for it. After all, he was responsible for losing Mom's inheritance, right?
Wow, knew about the CC but not the inheritance. Sad, really.
GC clearly made mistakes with AMBS. He appears to have learned from those and is doing things a lot smarter these days with TOMDF. Still, it's an OTC company and fundraising is hard in this arena. Dilutive funding is a way of life here. Glad we finally have it all now in the hands of investors who back us and won't exit for a quick profit at shareholders expense.
And agreed there still appears to be runway for a rebirth of Amarantus. I picked up some shares of AMBS last week with that possibility in mind... already in the green on those. Going to hold those and see where it all ends up. If it doesn't pan out, I promise not to blame the CEO. My money, my decision to invest.
Really hoping those who held on to AMBS through all the difficult years are able to reap their rewards. Interesting times ahead for both Todos and Amarantus.
Agreed with lots happening, and same here holding for Videssa, although my initial interest in Todos was directly related to the coronavirus involvement. My interest grew as I learned more about the company, and the amount I invested grew along with that.
Heavily invested now but understand it's still a risky small OTCQB company, more shares than the CEO (at least what has been reported on Form 4) but will not blame him, like some, if it doesn't work out. Investing is always a risk, but I feel confident with this investment. Will probably take some off the table if we get a big spike on a buyout or partnering offer for Tollovir, but will continue to hold the majority of my shares.
Looking forward to the presentation tomorrow. Hoping we learn something new about how this story is unfolding.
One of the risks of being invested in a small company, even if the technology is awesome.
Have to disagree with you on the earnings front. Generally that is the long-held tradition. But we've both seen plenty of companies that have high share prices even when earnings are still years away. Hype and potential earnings drive many stock prices. Earnings have to show up at some point but realistically news of a potential Covid killer can send the share price soaring long before earnings show up.
I'm hopeful the new team can generate the contracts and revenues we expect.
I'm not only excited about upcoming phase 2 data, but also the potential for the TolloTest. From my understanding, this test will measure for presence of the 3CL protease which is created in large numbers by the virus immediately after infection, at 70 times the number of viral protein chains, so it's likely the best early indicator of infection. These virus-produced enzymes should be detectable even earlier than the virus itself via the PCR method.
Getting this detection method approved and in a format that allows rapid testing will be a game changer. PCR testing, while highly accurate, takes too long for screening at events, family gatherings, and when used for travel leaves the window open for infections occurring in the window between testing and travel. Quick tests that measure antibodies are useless as a person can be infected and transmissible for days or a week before the antibodies show up to be detected. The 3CL protease suppresses the body's initial immune response to allow time for the virus to rapidly spread. A quick test for 3CL protease presence at the initial stages of infection would be the Holy Grail of testing and greatly limit spread of the virus.
Gerald hinted at this being a quick test in the recent investor conference call, I believe. If they're able to perfect the technology and package it in a kit that can be used in schools, prior to events, at home, etc., that changes the dynamics of the pandemic and we start managing treatments with antivirals like Tollovir and Paxlovid instead of advocating more and more boosters.
I'm thinking the last tweet I posted from 12/20/21 might be related to the TolloTest.
Clueless about what transpired back then... granted, I'll give you that. However, I asked a question and you won't answer whether or not AMBS shares were unloaded after learning of Fessler's involvement. You seem to know all about the guy and are calling the CEO a moron because he let this snake into the mix. But did you know that at the time or was it years later?
Unable to answer because answering honestly points to someone else besides Gerald as being a moron. Just admit it and we can move on. Again, you brought up the topic. I'm just asking for clarification. How about an honest answer, brother. Or is that too much for readers to expect?
I'm going to back off posting daily CEO tweets and just post the ones that add additional insight into what the company is doing. It will be less work and better content for the board to discuss. Thanks to those who provided feedback.
Picked up more Todos shares this morning. Ready for trial data and subsequent NASDAQ uplist. Bring it on!!
I am relaxed. We know there are shares being issued to NLC and Dr. Arad. My expectations for valuation of a partnership or buyout of 3CL Sciences is based on one billion shares issued, so it's still in line with my projections.
That's my point. I had no idea what was happening because I wasn't invested in AMBS. But you were. So did you know about Fessler at the time or not? And if so, did you unload your shares at the time? Or later when the dealings with Fessler became clearer?
If not selling at first sign of Fessler's involvement, then Gerald was not the only moron involved with their AMBS investment.
Why can't you simply answer the question? I'm pretty sure I know why.
I don't worship the CEO. I'm just asking a logical question. I guess expecting an honest answer is too much to ask.
And, you're the one that brought it up, dragging up something that happened many years ago. If Gerald did cause the problem at least he's cleaning it up now. Some just like to live in the past. Try focusing on investments you're currently in instead of axe grinding from the past.
But if we are axe grinding again, perhaps it's time for Thornton Melon to visit the MONI board and make another post about the dismal decline in share price over the last 6 months. I no longer have an investment there, but what the hell, that's not a requirement to post, is it? Just glad I got out of that dog. I took a 600K position in AMBS and it's already green.
Did you unload your AMBS shares as soon as you found out Fessler was involved? If not, then more than just the CEO was a moron, wouldn't you say?
Serious question. Hindsight is always 20/20. Harder to see with such clarity at the time.
Info on iiiNTENT: https://www.iiintent.io/
Looks like they'll be doing some of they heavy lifting as well. Great combination of talent and technology to drive product awareness and sales.
NEWS: Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
• Company retains iiiNTENT SAAS artificial intelligence marketing service for Tollovid® and Tollovid Daily™ 3CL protease inhibitor dietary supplement products
NEW YORK, NY and TEL AVIV, Israel , Dec. 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has appointed Mr. Valentino Smith, MBA as Vice President of Marketing. Mr. Smith brings over ten years of marketing experience to Todos, including brick & mortar and digital marketing for consumer packaged goods, healthcare services & information, over-the-counter (OTC) supplement and pharmaceutical products.
“I am very excited to be joining Todos, especially as the Company begins to market Tollovid and Tollovid Daily, and as the Company prepares to engage with regulatory agencies worldwide regarding Tollovir™, the Company’s oral antiviral drug candidate for COVID-19 is currently in a Phase 2 trial for hospitalized patients,” said Valentino Smith, MBA, Vice President of Marketing at Todos. “I see tremendous opportunity for growth and I’m looking forward to driving the effort going forward just as we are seeing a massive surge in the need for high throughput rapid turnaround SARS-CoV-2 PCR testing as the Omicron variant takes hold across the United States.”
Mr. Valentino joins Todos with over 10 years of marketing experience in healthcare. Most recently, Mr. Valentino was the Omni-Channel Engagement Lead for Novartis Oncology where he developed media plans and led the execution of global digital solutions for Piqray’s early launch. Prior to Novartis, Mr. Smith served as Associate Director of Global Marketing for Merck, where he drove scientific engagement plans with Medical Affairs by identifying new ways to interact and partner with healthcare professionals and various patient advocacy groups. Prior to Merck, Mr. Smith worked in various marketing roles at WebMD and McCann Healthcare / Grey Healthcare Group. Mr. Valentino is currently an Adjunct Assistant Professor of Marketing at Long Island University and received his undergraduate and MBA degrees from Long Island University.
Concurrent with this announcement, the Company retained the services of iiiNTENT, an artificial intelligence digital marketing software as a service (SAAS) to assist with the marketing of 3CL protease inhibitor dietary supplement immune support products Tollovid® and Tollovid Daily™.
“We are very excited to be partnering with Todos Medical on the pending marketing campaigns for Tollovid and Tollovid Daily,” said Chase Gibson, Co-CEO of iiiNTENT. “This appears to be an extremely timely product and we believe we can drive substantial traffic with high conversion rates given highly motivated personas we intend to target.”
“We are now in growth mode for our commercial products and services from our Tollovid & Tollovid Daily products to our COVID testing services that we are currently offering from our Provista Diagnostics CLIA/CAP laboratory,” said Gerald E. Commissiong, President & CEO of Todos Medical. “Valentino’s extensive background in marketing key healthcare-based products at the highest levels has prepared him for the challenges in helping us engage with clients and customers for our diverse array of products & services that address key bottlenecks that currently exist in our healthcare system. We are also very excited about working with iiiNTENT to drive growth for our Tollovir brand of products, as we believe that could be a big driver of revenue growth heading into 2022.”
https://investor.todosmedical.com/news-events/press-releases/detail/166/todos-medical-appoints-valentino-smith-mba-as-vice
Most of what the CEO posts on Twitter is regarding Todos, and I copy those daily over on the Todos board for those who don't have Twitter accounts. When I see a post about Amarantus I try to post it here as well. There's just not that many, but I suspect that will change soon.
Things going on behind the scenes with AMBS. Hopefully updates will be released in the coming weeks.
Question for the board... given the extreme number of Twitter posts on 12/17, should I continue to post everything or should I filter the posts to only those answering questions about the company? In other words, I would omit posts where Gerald is responding to a news story or a post made by a medical professional, etc.
I don't mind doing it either way, but the post for 12/17 took several hours of combing through responses to get things organized. I know some already have Twitter access and are following Gerald on Twitter. But for those who don't, is what I'm posting of any value if it's not providing additional info about the company's plans, products, etc?
Looking for feedback.
Share Structure Update - 12/17/21
24,574,842 shares added since last update on 12/10/21.
https://www.otcmarkets.com/stock/TOMDF/security
Attention Tollovid Daily users: The holiday special for "Buy One Bottle and Get Second Bottle Half Off" applies to both products, not just full-strength Tollovid. I initially thought it was only for Tollovid but just placed an order for my second bottle of Tollovid Daily and was offered another bottle at half price. I took it and that lowered price to $74.25 per bottle. Get 'em while they last.
Already heavily invested in Todos shares but now have a stake in Amarantus as well. Overall in the green on both investments.
Added 600K AMBS shares this morning. Seems a no-brainer with what is unfolding with Todos Medical.